InvestSMART

Echo IQ Limited (ASX: EIQ) - Announcements

Current share price for EIQ : $1.375 0.045 (3.38%)+

ASX company news and announcements for Echo IQ Limited (EIQ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Echo IQ Limited (EIQ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Echo IQ Limited (EIQ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Echo IQ Limited (EIQ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$1,017 Notification regarding unquoted securities - EIQ 6 Mar 2025 7:03PM $0.270 $1.375 risen by 409.26%
$1,017 Notification regarding unquoted securities - EIQ 6 Mar 2025 7:02PM $0.270 $1.375 risen by 409.26%
$1,017 Notification regarding unquoted securities - EIQ 6 Mar 2025 7:02PM $0.270 $1.375 risen by 409.26%
$1,017 Notification of cessation of securities - EIQ 6 Mar 2025 5:30PM $0.270 $1.375 risen by 409.26%
$1,017 Investor Webinar 6 Mar 2025 9:18AM $0.265 $1.375 risen by 418.87%
$1,017 Strong Progress in First Two Months of CY25 Achieved 5 Mar 2025 9:32AM $0.245 $1.375 risen by 461.22%
$1,017 Proposed issue of securities - EIQ 3 Mar 2025 2:40PM $0.260 $1.375 risen by 428.85%
$1,017 Half Year Accounts 31 December 2024 27 Feb 2025 4:11PM $0.285 $1.375 risen by 382.46%
$1,017 Appendix 4D 31 December 2024 27 Feb 2025 4:06PM $0.285 $1.375 risen by 382.46%
$1,017 $1.26M R&D TAX INCENTIVE RECEIVED 12 Feb 2025 2:29PM $0.280 $1.375 risen by 391.07%
$1,017 Notification of cessation of securities - EIQ 4 Feb 2025 3:39PM $0.243 $1.375 risen by 467.01%
$1,017 Response to ASX Query Letter 31 Jan 2025 1:53PM $0.265 $1.375 risen by 418.87%
$1,017 Quarterly Activities Report and Appendix 4C Cash Flow Report 30 Jan 2025 2:07PM $0.245 $1.375 risen by 461.22%
$1,017 Commencement of Chief Executive Officer 14 Jan 2025 9:39AM $0.245 $1.375 risen by 461.22%
$1,017 PRE-SUBMISSION MEETING WITH US FDA FOR HEART FAILURE 24 Dec 2024 9:07AM $0.235 $1.375 risen by 485.11%
$1,017 Initial Director's Interest Notice 18 Dec 2024 12:33PM $0.230 $1.375 risen by 497.83%
$1,017 Change of Director's Interest Notice 18 Dec 2024 12:19PM $0.230 $1.375 risen by 497.83%
$1,017 Notification of cessation of securities - EIQ 18 Dec 2024 12:14PM $0.230 $1.375 risen by 497.83%
$1,017 Proposed issue of securities - EIQ 18 Dec 2024 12:11PM $0.230 $1.375 risen by 497.83%
$1,017 Proposed issue of securities - EIQ 18 Dec 2024 12:02PM $0.230 $1.375 risen by 497.83%
$1,017 Final Director's Interest Notice 13 Dec 2024 12:33PM $0.240 $1.375 risen by 472.92%
$1,017 APPOINTMENT OF LEADING CARDIAC FOCUSSED US-BASED NED 12 Dec 2024 9:35AM $0.250 $1.375 risen by 450%
$1,017 The First Step in EIQs US Market Commercialisation Strategy 9 Dec 2024 9:01AM $0.260 $1.375 risen by 428.85%
$1,017 S&P DJI Announces December 2024 Quarterly Rebalance 6 Dec 2024 5:08PM $0.260 $1.375 risen by 428.85%
$1,017 EIQ signs integration agreement with Flagship US Hospital 18 Nov 2024 9:40AM $0.225 $1.375 risen by 511.11%

126 - 150 of 381 results

Page 6 of 16

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.